CN107325071A - A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect - Google Patents
A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect Download PDFInfo
- Publication number
- CN107325071A CN107325071A CN201710415347.6A CN201710415347A CN107325071A CN 107325071 A CN107325071 A CN 107325071A CN 201710415347 A CN201710415347 A CN 201710415347A CN 107325071 A CN107325071 A CN 107325071A
- Authority
- CN
- China
- Prior art keywords
- hickory
- preparation
- ethanol
- hypoglycemic effect
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000723418 Carya Species 0.000 title claims abstract description 46
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- ORJDDOBAOGKRJV-CQSZACIVSA-N (2S)-Pinocembrin Natural products C1([C@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-CQSZACIVSA-N 0.000 title 1
- ORJDDOBAOGKRJV-UHFFFAOYSA-N Dihydrotectochrysin Natural products O1C2=CC(OC)=CC(O)=C2C(=O)CC1C1=CC=CC=C1 ORJDDOBAOGKRJV-UHFFFAOYSA-N 0.000 title 1
- ORJDDOBAOGKRJV-AWEZNQCLSA-N pinostrobin Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)OC)=CC=CC=C1 ORJDDOBAOGKRJV-AWEZNQCLSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 13
- LIOOJQZRNLJKMU-UHFFFAOYSA-N Demethyl coniferin Natural products OCC=Cc1ccc(OC2OC(CO)C(O)C(O)C2O)c(O)c1 LIOOJQZRNLJKMU-UHFFFAOYSA-N 0.000 claims abstract description 11
- SFLMUHDGSQZDOW-FAOXUISGSA-N coniferin Chemical compound COC1=CC(\C=C\CO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-FAOXUISGSA-N 0.000 claims abstract description 11
- LIOOJQZRNLJKMU-UXXRCYHCSA-N coniferin Natural products OCC=Cc1ccc(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(O)c1 LIOOJQZRNLJKMU-UXXRCYHCSA-N 0.000 claims abstract description 11
- SFLMUHDGSQZDOW-IBEHDNSVSA-N coniferoside Natural products COC1=CC(C=CCO)=CC=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 SFLMUHDGSQZDOW-IBEHDNSVSA-N 0.000 claims abstract description 11
- IKUQEFGEUOOPGY-UHFFFAOYSA-N euoniside Natural products COC1=CC=2C=CC(=O)OC=2C(OC)=C1OC1OC(CO)C(O)C(O)C1O IKUQEFGEUOOPGY-UHFFFAOYSA-N 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 239000000287 crude extract Substances 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 18
- 241001453450 Carya illinoinensis Species 0.000 claims description 16
- 235000009025 Carya illinoensis Nutrition 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000004952 Polyamide Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 229920002647 polyamide Polymers 0.000 claims description 10
- 241000899834 Obovaria olivaria Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000013078 crystal Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 239000012259 ether extract Substances 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 235000007731 Pinus pungens Nutrition 0.000 claims description 2
- 241000369906 Pinus pungens Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003405 delayed action preparation Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 238000000643 oven drying Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- SKBXVAOMEVOTGJ-UHFFFAOYSA-N xi-Pinol Chemical compound CC1=CCC2C(C)(C)OC1C2 SKBXVAOMEVOTGJ-UHFFFAOYSA-N 0.000 claims 2
- 102100038374 Pinin Human genes 0.000 claims 1
- 101710173952 Pinin Proteins 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 13
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 6
- 230000000225 effect on diabetes Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 238000010172 mouse model Methods 0.000 description 7
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 3
- 238000013116 obese mouse model Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011549 crystallization solution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000036391 Genetic obesity Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241000758789 Juglans Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000037493 inherited obesity Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种具有降血糖作用的山核桃叶球松素的制备方法和用途,含有球松素的质量百分比在90%以上。该山核桃叶球松素能够显著降低糖尿病小鼠的血糖水平,对于糖尿病特别是II型糖尿具有显著疗效,可用于防治糖尿病为主要功能的药品和保健产品。The invention relates to a preparation method and application of hickory coniferin with hypoglycemic effect, and the mass percentage of coniferin containing is more than 90%. The hickory yew coniferin can significantly reduce the blood sugar level of diabetic mice, has a significant curative effect on diabetes, especially type II diabetes, and can be used in medicines and health care products whose main function is to prevent and treat diabetes.
Description
技术领域technical field
本发明涉及医药技术领域,特别涉及一种具有降血糖作用的山核桃叶球松素的制备方法和用途。The invention relates to the technical field of medicines, in particular to a preparation method and application of hickory pecan yewetine with hypoglycemic effect.
背景技术Background technique
糖尿病是由血液中葡萄糖堆积过多引起的代谢性疾病,危急免疫功能。也因其病程较长人体的麻烦随之而至,糖尿病患者很容隐感染由感冒、肺炎、肺结核引起的多种感染疾病,并且不易治愈。严重的可能引起全身多器官损害,出现失明、肾病等并发症,危害人体健康。糖尿病一般分1型糖尿病、2型糖尿病、妊娠糖尿病及其他特殊类型的糖尿病。在糖尿病患者中,2型糖尿病所占的比例约为95%。随着今年来居民生活水平的提高,糖尿病患者的数量也大大增加,这也造成大量降血糖药物随之问世,但目前临床上常见糖尿病治疗药物多为化学合成类药物,虽然疗效确切,也同时存在较多不良反应。天然药物,是经现代医药体系证明的具有一定药理活性的动物药、植物药和矿物药等。Diabetes is a metabolic disease caused by excess accumulation of glucose in the blood, which can compromise immune function. Also because of its longer course of disease, the troubles of the human body follow. Diabetics are easily infected with various infectious diseases caused by colds, pneumonia, and tuberculosis, and are difficult to cure. Severe cases may cause damage to multiple organs throughout the body, blindness, kidney disease and other complications, endangering human health. Diabetes is generally divided into type 1 diabetes, type 2 diabetes, gestational diabetes and other special types of diabetes. Type 2 diabetes accounts for approximately 95% of diabetic patients. With the improvement of residents' living standards this year, the number of diabetic patients has also increased greatly, which has also led to the advent of a large number of hypoglycemic drugs. However, most of the commonly used clinical diabetes treatment drugs are chemical synthetic drugs. There are many adverse reactions. Natural medicines are animal medicines, herbal medicines and mineral medicines with certain pharmacological activities proved by the modern medicine system.
社会的发展使人们越来越关注化学药品的负面影响,在这种背景下,中草药无疑具有不可取代的优势。因此,开发具有预防及治疗糖尿病及其并发症的中草药既迎合市场需求又具有良好的社会效益。The development of society has made people pay more and more attention to the negative effects of chemicals. In this context, Chinese herbal medicine has irreplaceable advantages. Therefore, the development of Chinese herbal medicines for the prevention and treatment of diabetes and its complications not only meets the market demand but also has good social benefits.
ob/ob小鼠是瘦素基因敲出所获得的一种先天性肥胖小鼠,其发病过程与人类肥胖相似,是较常用的遗传性肥胖模型之一,也常用于二型糖尿病动物实验研究。The ob/ob mouse is a congenitally obese mouse obtained by knocking out the leptin gene. Its pathogenesis is similar to that of human obesity. It is one of the more commonly used genetic obesity models and is also commonly used in animal experiments for type 2 diabetes.
山核桃树是一种胡桃科落叶乔木,其叶多在夏秋两季采收,入药具有清热解毒、杀虫止痒的功效。主要用于脚趾湿痒及皮肤癣证的治疗等。研究发现山核桃叶提取物中含有大量抗氧化活性物质,如黄酮等,具有抗衰老、抗肿瘤、抗血管生成等功效。黄酮类化合物是药用植物主要活性成分之一,具有广谱药理活性和较低毒性,研究表明山核桃叶球松素可降低模型ob/ob小鼠的血糖水平,可用于防治高血糖,特别是2型糖尿病为主要功能的药品及保健食品。Hickory is a deciduous tree of the Juglandaceae family. Most of its leaves are harvested in summer and autumn. It is used as medicine to clear away heat, detoxify, kill insects and relieve itching. It is mainly used for the treatment of toe wet itching and skin ringworm syndrome. Studies have found that hickory leaf extract contains a large number of antioxidant active substances, such as flavonoids, which have anti-aging, anti-tumor, and anti-angiogenesis effects. Flavonoids are one of the main active ingredients of medicinal plants, which have broad-spectrum pharmacological activity and low toxicity. Studies have shown that hickory carya pine can reduce blood sugar levels in model ob/ob mice, and can be used to prevent and treat hyperglycemia, especially It is a medicine and health food with type 2 diabetes as its main function.
发明内容Contents of the invention
本发明的目的在于提供一种具有降血糖作用的山核桃叶提取物球松素的制备方法,同时提供了其用途。The purpose of the present invention is to provide a preparation method of the hickory nut leaf extract bulbocenadin with hypoglycemic effect, and also provide its application.
本发明解决其技术问题所采用的技术方案是:The technical solution adopted by the present invention to solve its technical problems is:
一种具有降血糖作用的山核桃叶提取物球松素,含有球松素的质量百分比在90%以上。The hickory nut leaf extract ballconiferin with hypoglycemic effect contains more than 90% of the ballconiferin by mass.
一种具有降血糖作用的山核桃叶球松素的制备方法,所述制备方法包括以下步骤:A kind of preparation method of the hickory nut yew coniferin with hypoglycemic effect, described preparation method comprises the following steps:
(1)将山核桃叶置于烘箱中干燥,粉碎过筛,加入75-95%的乙醇回流提取,每次30-120分钟,重复1-3次,过滤,合并滤液;(1) Put hickory leaves in an oven to dry, crush and sieve, add 75-95% ethanol to reflux extraction, each time for 30-120 minutes, repeat 1-3 times, filter, and combine the filtrates;
(2)将步骤(1)的滤液浓缩,每4mL滤液加入0.7mL、1mol/L的氢氧化钠溶液,混匀后再添加聚酰胺充分混合,减压浓缩上柱,以4-12BV/h的流速,依次用水、20%乙醇、40%乙醇、60%乙醇洗脱,每种溶剂洗脱6-10倍柱体积,收集60%乙醇的洗脱液,减压浓缩至干燥得山核桃叶粗提物;(2) Concentrate the filtrate of step (1), add 0.7mL, 1mol/L sodium hydroxide solution to every 4mL filtrate, mix well, then add polyamide and mix thoroughly, concentrate under reduced pressure and put on the column, at 4-12BV/h The flow rate is successively eluted with water, 20% ethanol, 40% ethanol, and 60% ethanol, and each solvent is eluted for 6-10 times of column volume, and the eluate of 60% ethanol is collected, concentrated under reduced pressure to dryness to obtain hickory leaves crude extract;
(3)将步骤(2)的山核桃叶粗提物按照每1g山核桃叶粗提取物加5-35mL甲醇的比例加入甲醇,并以石油醚1:1比例进行萃取,重复3-10次,然后将石油醚萃取液于30-50℃减压浓缩至干燥,即得山核桃叶黄色粗提取物;(3) Add methanol to the pecan leaf crude extract in step (2) according to the ratio of 5-35mL methanol per 1g of pecan leaf crude extract, and extract with petroleum ether in a ratio of 1:1, repeat 3-10 times , and then concentrate the petroleum ether extract to dryness under reduced pressure at 30-50°C to obtain the yellow crude extract of hickory nut leaves;
(4)将步骤(3)的山核桃叶黄色粗提取物以1g:8-12mL的比例,加入60vol%-90%乙醇水溶液,在70-90℃水浴中进行溶解,溶解结束后,迅速放于4℃冰箱中,放置12-24h,进行结晶,滤纸过滤,得到山核桃叶球松素晶体,球松素含量在90%以上。(4) Add 60vol%-90% aqueous ethanol solution to the yellow crude extract of pecan leaves in step (3) in a ratio of 1g:8-12mL, and dissolve it in a water bath at 70-90°C. Place in a refrigerator at 4° C. for 12-24 hours for crystallization, and filter through filter paper to obtain hickory coniferin crystals, the content of which is more than 90%.
作为优选,步骤(1)中烘箱干燥温度为30-80℃。Preferably, the oven drying temperature in step (1) is 30-80°C.
作为优选,步骤(1)过筛筛目为40-100目。Preferably, the sieve mesh in step (1) is 40-100 mesh.
作为优选,步骤(1)中提取条件为常压60-120℃。As a preference, the extraction condition in step (1) is 60-120° C. under normal pressure.
作为优选,步骤(1)中70-95%乙醇水溶液用量为每1g山核桃叶粉碎物加10mLAs preferably, the consumption of 70-95% ethanol aqueous solution in step (1) is to add 10mL per 1g hickory leaf pulverization
作为优选,步骤(2)中聚酰胺的用量为每100mL碱化后的滤液添加5g聚酰胺。As a preference, the amount of polyamide used in step (2) is to add 5 g of polyamide per 100 mL of alkalized filtrate.
一种具有降血糖作用的山核桃叶球松素的用途,将上述制备的山核桃叶球松素与药剂或者食品上认可的辅料,采用现代制剂技术,制成以山核桃叶球松素为主的胶囊剂、片剂、散剂、口服液、软胶囊、丸剂、凝胶剂、缓释制剂等各种剂型及保健食品。A use of hickory jaggery with hypoglycemic effect, the hickory jaggery prepared above and pharmaceutical or food approved adjuvant, using modern preparation technology, made hickory jelly jelly as the The main capsules, tablets, powders, oral liquids, soft capsules, pills, gels, sustained-release preparations and other dosage forms and health food.
本发明的有益效果:本发明以胡桃科山核桃叶为原料制备其初提物,并经进一步纯化获得具有降血糖作用的山核桃叶球松素,该方法简单易行,且进一步扩大了山核桃叶的应用范围,具有十分巨大的市场潜力和经济价值。Beneficial effect of the present invention: the present invention uses the leaves of Juglandaceae hickory as raw material to prepare its primary extract, and further purifies to obtain the hickory leaf condylopin with hypoglycemic effect. This method is simple and easy, and further expands the The scope of application of walnut leaves has very huge market potential and economic value.
具体实施方式detailed description
下面通过具体实施例对本发明作进一步详细的説明,但本发明并不限于这些实施例。The present invention will be described in further detail below through specific examples, but the present invention is not limited to these examples.
实施例1Example 1
山核桃叶于40℃烘干,粉碎,过40目筛,称取粉末100g,加入1L体积浓度85%乙醇溶液回流提取,2次,提取条件为常压80℃,每次60min,合并滤液,每4mL滤液加入0.7mL、1mol/L的氢氧化钠溶液碱化12h,碱化后将样品溶液每100mL加入5g聚酰胺(100-200目)比例混合均匀,减压浓缩至干燥,上层析柱(15mm×350mm i.d),依次用10BV的水、20%乙醇、40%乙醇、60%乙醇洗脱,收集60%乙醇洗脱液,减压浓缩至干燥,获得山核桃叶粗提物。Hickory leaves were dried at 40°C, crushed, passed through a 40-mesh sieve, weighed 100g of the powder, added 1L of 85% ethanol solution for reflux extraction, twice, the extraction conditions were normal pressure 80°C, 60min each time, and the filtrates were combined. Add 0.7mL, 1mol/L sodium hydroxide solution to each 4mL filtrate to alkalize for 12h. After alkalization, add 5g polyamide (100-200 mesh) to the sample solution per 100mL and mix evenly. Concentrate to dryness under reduced pressure and perform chromatography. The column (15mm×350mm i.d) was sequentially eluted with 10BV of water, 20% ethanol, 40% ethanol, and 60% ethanol, and the 60% ethanol eluate was collected and concentrated to dryness under reduced pressure to obtain the crude extract of hickory nut leaves.
将上述山核桃叶粗提物按照每1g山核桃叶粗提物加入5mL甲醇的比例进行溶解,再用等体积石油醚萃取10次,将石油醚产物减压旋转蒸发至干燥,获得山核桃叶黄色粗提物。将山核桃叶黄色粗提物溶解于90℃、80%乙醇中,趁热过滤,并将滤液迅速放于4℃冰箱中,放置12h,结晶。将结晶液滤纸过滤,得到山核桃叶提取物球松素晶体,球松素含量在90%以上。The above-mentioned hickory leaf crude extract is dissolved according to the ratio of adding 5mL of methanol per 1g of hickory leaf crude extract, and then extracted 10 times with an equal volume of petroleum ether, and the petroleum ether product is evaporated to dryness under reduced pressure to obtain hickory leaf Yellow crude extract. Dissolve the yellow crude extract of pecan leaves in 80% ethanol at 90°C, filter while hot, and quickly put the filtrate in a refrigerator at 4°C for 12 hours to crystallize. The crystallization solution is filtered through a filter paper to obtain condyloconolin crystals of the hickory leaf extract, and the content of condyloconolin is more than 90%.
实施例2Example 2
将山核桃叶置于35℃烘箱干燥,粉碎,过80目筛,称取山核桃叶粉末200g,加入2L体积浓度95%乙醇回流提取,提取条件为常压60℃,2次,每次30min,合并滤液,每4mL滤液加入0.7mL、1mol/L的氢氧化钠溶液碱化12h,碱化后将样品溶液每100mL加入5g聚酰胺(100-200目)比例混合均匀,减压浓缩至干燥,上层析柱(15mm×350mm i.d),依次用10BV的水、20%乙醇、40%乙醇、60%乙醇洗脱,收集60%乙醇洗脱液,减压浓缩至干燥,获得山核桃叶粗提物。Place hickory leaves in a 35°C oven to dry, crush, pass through an 80-mesh sieve, weigh 200g of hickory leaf powder, add 2L volume concentration of 95% ethanol for reflux extraction, and the extraction conditions are atmospheric pressure 60°C, 2 times, 30min each time , combine the filtrates, add 0.7mL, 1mol/L sodium hydroxide solution to each 4mL filtrate to alkalinize for 12h, after alkalization, add 5g polyamide (100-200 mesh) to the sample solution per 100mL and mix evenly, concentrate to dryness under reduced pressure , upper chromatographic column (15mm * 350mm i.d), with the water of 10BV, 20% ethanol, 40% ethanol, 60% ethanol elution successively, collect 60% ethanol eluate, concentrate under reduced pressure to dryness, obtain pecan leaf crude extract.
将上述山核桃叶粗提物按照每1g山核桃叶粗提物加入20mL甲醇的比例进行溶解,再用等体积石油醚萃取10次,将石油醚产物减压旋转蒸发至干燥,获得山核桃叶黄色粗提物。将山核桃叶黄色粗提物溶解于90℃、80%乙醇中,趁热过滤,并将滤液迅速放于4℃冰箱中,放置12h,结晶。将结晶液滤纸过滤,得到山核桃叶提取物球松素晶体,球松素含量在90%以上。The above-mentioned hickory leaf crude extract is dissolved according to the ratio of adding 20mL of methanol per 1g of hickory leaf crude extract, and then extracted 10 times with an equal volume of petroleum ether, and the petroleum ether product is evaporated to dryness under reduced pressure to obtain hickory leaf Yellow crude extract. Dissolve the yellow crude extract of pecan leaves in 80% ethanol at 90°C, filter while hot, and quickly put the filtrate in a refrigerator at 4°C for 12 hours to crystallize. The crystallization solution is filtered through a filter paper to obtain condyloconolin crystals of the hickory leaf extract, and the content of condyloconolin is more than 90%.
实施例3Example 3
将山核桃叶置于烘箱中80℃干燥,粉碎过100目筛,称取山核桃叶粉末300g,加入3L体积浓度75%的乙醇回流提取,提取条件为常压120℃,每次120分钟,重复1次,过滤,合并滤液;Hickory leaves are placed in an oven to dry at 80°C, crushed through a 100-mesh sieve, weigh 300g of hickory leaf powder, add 3L of ethanol with a volume concentration of 75% for reflux extraction, and the extraction conditions are 120°C at normal pressure, 120 minutes each time, Repeat once, filter, and combine the filtrates;
(2)将步骤(1)的滤液浓缩,每4mL滤液加入0.7mL、1mol/L的氢氧化钠溶液,碱化12h后再添加聚酰胺充分混合,每100mL碱化后的滤液添加5g聚酰胺;减压浓缩上柱,以12BV/h的流速,依次用水、20%乙醇、40%乙醇、60%乙醇洗脱,每种溶剂洗脱6-10倍柱体积,收集60%乙醇的洗脱液,减压浓缩至干燥得山核桃叶粗提物;(2) Concentrate the filtrate of step (1), add 0.7mL, 1mol/L sodium hydroxide solution for every 4mL of filtrate, add polyamide after alkalization for 12h and mix thoroughly, add 5g of polyamide for every 100mL of alkalized filtrate Concentrate under reduced pressure and put on the column, with a flow rate of 12BV/h, sequentially elute with water, 20% ethanol, 40% ethanol, and 60% ethanol, each solvent is eluted for 6-10 times the column volume, and the elution of 60% ethanol is collected. liquid, concentrated under reduced pressure to dryness to obtain the crude extract of pecan leaves;
(3)将步骤(2)的山核桃叶粗提物按照每1g山核桃叶粗提取物加35mL甲醇的比例加入甲醇,并以石油醚1:1比例进行萃取,重复3次,然后将石油醚萃取液于30-50℃减压浓缩至干燥,即得山核桃叶黄色粗提取物;(3) Add methanol to the pecan leaf crude extract of step (2) according to the ratio of 35mL methanol for every 1g pecan leaf crude extract, and extract with sherwood oil 1:1 ratio, repeat 3 times, then add petroleum Concentrate the ether extract to dryness under reduced pressure at 30-50°C to obtain the yellow crude extract of pecan leaves;
(4)将步骤(3)的山核桃叶黄色粗提取物以1g:12mL的比例,加入90%乙醇水溶液,在70℃水浴中进行溶解,溶解结束后,迅速放于4℃冰箱中,放置24h,进行结晶,滤纸过滤,得到山核桃叶球松素晶体,球松素含量在90%以上。(4) Add 90% ethanol aqueous solution to the yellow crude extract of pecan leaves in step (3) in a ratio of 1g:12mL, and dissolve it in a water bath at 70°C. After the dissolution, quickly put it in a refrigerator at 4°C and place After 24 hours, carry out crystallization, and filter with filter paper to obtain hickory coniferin crystals, the content of which is more than 90%.
球松素含量测定方法参见沈勇等.高效液相色谱法测定山核桃叶中5个黄酮苷元含量[J].药物分析杂志,2013年05期。See Shen Yong et al. Determination of 5 flavonoid aglycones in hickory leaves by high performance liquid chromatography [J]. Journal of Pharmaceutical Analysis, 2013-05.
山核桃叶球松素对四氧嘧啶致致高血糖小鼠模型的作用研究Study on the effect of hickory carya phyllopine on the mouse model of hyperglycemia induced by alloxan
1.实验方法:1. Experimental method:
将雄性ICR小鼠50只,随机分为6组,其中空白对照组10只,其余各组各8只,将40只模型小鼠禁食12h后尾静脉注射四氧嘧啶溶液80mg/kg造摸(正常对照组注射等量生理盐水),5d后测血糖,当血糖>11.1mmol/L时造模成功。然后将模型小鼠随机分为5组,分别为高血糖模型组,山核桃叶球松素50mg/kg低剂量组、100mg/kg中剂量组、200mg/kg高剂量组,50mg/kg二甲双胍阳性药组。实验期间正常对照组及模型组给予0.5%CMC-Na灌胃,其余各组按给药剂量灌胃,1次/d,连续14d。14d后,测定各组小鼠血糖、体重及血清果糖胺,并记录。实验结果均利用SPSS 18.0统计软件进行统计学处理。实验数据均以平均数±标准差表示,采用单因素方差分析,P<0.05时认为有显著性差异。50 male ICR mice were randomly divided into 6 groups, including 10 blank control groups, and 8 mice in each of the other groups. After fasting for 12 hours, 40 model mice were injected with alloxan solution 80mg/kg into the tail vein to make a model. (The normal control group was injected with the same amount of normal saline), blood glucose was measured 5 days later, and the model was successfully established when the blood glucose was >11.1mmol/L. Then the model mice were randomly divided into 5 groups, which were the hyperglycemia model group, the low-dose group of 50mg/kg hickory cypressin, the middle-dose group of 100mg/kg, the high-dose group of 200mg/kg, and the 50mg/kg metformin positive group. medicine group. During the experiment, the normal control group and the model group were given 0.5% CMC-Na orally, and the other groups were given intragastric administration according to the dose, once a day, for 14 consecutive days. After 14 days, the blood glucose, body weight and serum fructosamine of mice in each group were measured and recorded. The experimental results were statistically processed using SPSS 18.0 statistical software. The experimental data are expressed as mean ± standard deviation, using one-way analysis of variance, when P < 0.05, there is a significant difference.
2.实验结果2. Experimental results
结果一见表1、表2,由表中可知山核桃叶球松素可以显著降低小鼠血糖含量,对四氧嘧啶致高血糖小鼠模型具有显著作用。The results are shown in Table 1 and Table 2. From the table, it can be known that hickory carya pachypinin can significantly reduce the blood sugar content of mice, and has a significant effect on the mouse model of hyperglycemia induced by alloxan.
表1山核桃叶球松素对高血糖模型小鼠的影响Table 1 The effect of hickory phyllopine on hyperglycemia model mice
注:与正常组比较,**P<0.01;与模型组比较,#P<0.05,##P<0.01。Note: Compared with the normal group, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.
表2山核桃叶总黄酮不同给药剂量对高血糖小鼠体重的影响Table 2 Effects of different dosages of total flavonoids from pecan leaves on the body weight of hyperglycemic mice
注:与正常组比较,**P<0.01;与模型组比较,#P<0.05。Note: Compared with the normal group, ** P<0.01; compared with the model group, # P<0.05.
山核桃叶球松素对ob/ob肥胖小鼠模型的作用研究Study on the effect of hickory phyllocinin on ob/ob obese mouse model
1.实验方法1. Experimental method
取8周龄ob/ob雄性小鼠40只,适应性饲养l周,然后将小鼠随机分为山核桃叶球松素50mg/kg低剂量组、100mg/kg中剂量组、200mg/kg高剂量组,50mg/kg黄连素阳性药组,并以C57小鼠作为正常对照组,各组小鼠1次/天灌胃。连续28d。28d后,测定各组小鼠血糖并记录。实验结果均利用SPSS 18.0统计软件进行统计学处理。实验数据均以平均数±标准差表示,采用单因素方差分析,P<0.05时认为有显著性差异。Take 40 8-week-old ob/ob male mice, feed them adaptively for 1 week, and then divide the mice into a low-dose group of 50 mg/kg of hickory leaf pinecone, a medium-dose group of 100 mg/kg, and a high-dose group of 200 mg/kg. Dosage group, 50mg/kg berberine positive drug group, and C57 mice as normal control group, mice in each group were administered orally once a day. 28 days in a row. After 28 days, the blood glucose of mice in each group was measured and recorded. The experimental results were statistically processed using SPSS 18.0 statistical software. The experimental data are expressed as mean ± standard deviation, using one-way analysis of variance, when P < 0.05, there is a significant difference.
2.实验结果2. Experimental results
实验结果见表3,由表中可知山核桃叶球松素可以显著降低小鼠血糖含量,对肥胖小鼠即II型糖尿病模型小鼠效果良好。The experimental results are shown in Table 3. It can be seen from the table that hickory pine pinulin can significantly reduce the blood sugar content of mice, and has a good effect on obese mice, that is, type II diabetes model mice.
表3山核桃叶球松素对ob/ob肥胖模型小鼠的影响Table 3 The effect of hickory phyllopine on ob/ob obesity model mice
注:与正常组比较,**P<0.01;与模型组比较,#P<0.05,##P<0.01。Note: Compared with the normal group, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01.
以上所述的实施例只是本发明的一种较佳的方案,并非对本发明作任何形式上的限制,在不超出权利要求所记载的技术方案的前提下还有其它的变体及改型。The above-described embodiment is only a preferred solution of the present invention, and does not limit the present invention in any form. There are other variations and modifications on the premise of not exceeding the technical solution described in the claims.
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710415347.6A CN107325071A (en) | 2017-06-05 | 2017-06-05 | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710415347.6A CN107325071A (en) | 2017-06-05 | 2017-06-05 | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107325071A true CN107325071A (en) | 2017-11-07 |
Family
ID=60194943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710415347.6A Pending CN107325071A (en) | 2017-06-05 | 2017-06-05 | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107325071A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109232757A (en) * | 2018-08-31 | 2019-01-18 | 吉首大学 | Walnut Leaves polyoses extract and application |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322132A (en) * | 1998-09-15 | 2001-11-14 | 韩国科学技术研究院 | Bioflavonoid as blood gloucose level lowering agent |
| CN1582919A (en) * | 2004-06-08 | 2005-02-23 | 华东师范大学 | Preparation of medicines for reducing blood sugar and triglyceride from hippophae rhamnoides flavone |
| CN101475459A (en) * | 2009-01-22 | 2009-07-08 | 浙江林学院 | Method for extracting pinostrobin and beta-sitosterin from hickory nut epicarp |
| CN103073530A (en) * | 2013-02-04 | 2013-05-01 | 河南中医学院 | Method fro preparing pinostrobin from lindera reflexa |
| CN103142685A (en) * | 2013-02-07 | 2013-06-12 | 浙江中医药大学 | Method for extraction of total flavonoid aglycones from hickory leaves |
| CN105362259A (en) * | 2015-10-20 | 2016-03-02 | 浙江中医药大学 | Chinese walnut leaf extract pinostrobin having uric acid reducing effect and preparation method thereof and application |
-
2017
- 2017-06-05 CN CN201710415347.6A patent/CN107325071A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1322132A (en) * | 1998-09-15 | 2001-11-14 | 韩国科学技术研究院 | Bioflavonoid as blood gloucose level lowering agent |
| CN1582919A (en) * | 2004-06-08 | 2005-02-23 | 华东师范大学 | Preparation of medicines for reducing blood sugar and triglyceride from hippophae rhamnoides flavone |
| CN101475459A (en) * | 2009-01-22 | 2009-07-08 | 浙江林学院 | Method for extracting pinostrobin and beta-sitosterin from hickory nut epicarp |
| CN103073530A (en) * | 2013-02-04 | 2013-05-01 | 河南中医学院 | Method fro preparing pinostrobin from lindera reflexa |
| CN103142685A (en) * | 2013-02-07 | 2013-06-12 | 浙江中医药大学 | Method for extraction of total flavonoid aglycones from hickory leaves |
| CN105362259A (en) * | 2015-10-20 | 2016-03-02 | 浙江中医药大学 | Chinese walnut leaf extract pinostrobin having uric acid reducing effect and preparation method thereof and application |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109232757A (en) * | 2018-08-31 | 2019-01-18 | 吉首大学 | Walnut Leaves polyoses extract and application |
| CN109232757B (en) * | 2018-08-31 | 2020-12-01 | 吉首大学 | Walnut leaf polysaccharide extract and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768152B (en) | Flos Osmanthi Fragrantis phenethyl alcohol glycoside extract and its production and use | |
| CN103070880B (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
| CN102771593A (en) | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method | |
| CN104547826B (en) | Galangal rhizome extract treats the medical usage of dysmenorrhoea | |
| CN105816489A (en) | Preparation method of durio zibethinus murr shell extract and application of durio zibethinus murr shell extract | |
| CN101322761B (en) | A kind of medicine for treating tracheitis and bronchitis and preparation method thereof | |
| CN104840527A (en) | Composition containing tenuifoliside and ginsenoside | |
| CN1965885A (en) | Application of total flavones of chickpea in preparation of medicament for treating diabetes | |
| CN104491372B (en) | A kind of Radix Scrophulariae buccal tablet | |
| CN107325071A (en) | A kind of preparation method and purposes of the Hickory Leaves pinostrobin with hypoglycemic effect | |
| CN102451260A (en) | Traditional Chinese medicine composition with fatigue relieving function and preparation method thereof | |
| CN102441064B (en) | Traditional Chinese medicine composition and its preparation for treating diabetes | |
| CN104013669A (en) | Method for preparing cyclocarya paliurus total flavonoid with effect of reducing blood glucose | |
| CN111803559B (en) | A kind of eggplant peel composition with hypoglycemic effect and preparation method and application thereof | |
| CN100563634C (en) | A kind of Herba Sidae Rhombifoliae soup drop pill | |
| CN1686424B (en) | A pharmaceutical composition containing Scutellaria baicalensis and Bupleurum bupleuri and its preparation method | |
| CN105055479B (en) | Hainan eye tree lotus water extract anti-inflammatory active ingredient and application | |
| CN119215089B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, resisting inflammation and reducing swelling, and preparation method and application thereof | |
| CN105288107B (en) | Compound hippophae rhamnoides clearing composition and preparation method thereof | |
| CN1931258B (en) | Preparation process and use of loquat seed extract | |
| CN105106263B (en) | Hainan eye tree lotus alcohol extracting thing anti-inflammatory active ingredient and application | |
| CN1939445B (en) | Preparation and use for loquat-leaf extract | |
| CN102488761A (en) | Traditional Chinese medicine composition for treating diabetes, preparation thereof and its preparation method | |
| CN110448622B (en) | Medicine for treating heat type cold and preparation method and application thereof | |
| CN102716231A (en) | Traditional Chinese medicinal composition for treating brain damage and brain edema and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171107 |